Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Apr 8, 2025
Trial Information
Current as of July 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at new ways to monitor lung cancer after surgery, specifically focusing on a type called non-small cell lung cancer. Researchers want to find out if using advanced blood tests to detect tiny amounts of cancer that may remain after surgery can help doctors make better treatment decisions and improve patient survival. They are particularly interested in how well these new methods work compared to traditional approaches and if they are effective for different groups of patients based on their cancer stage and other factors.
To participate in this trial, you need to be between 65 and 74 years old and have early-stage non-small cell lung cancer that requires surgery or certain types of treatment before surgery. You should also have specific types of nodules visible in imaging tests. Unfortunately, younger patients or those with more advanced cancer stages cannot join the study. If you qualify and decide to participate, you can expect to undergo some blood tests and follow-up care that may help guide your treatment after surgery. This research could lead to better options for managing lung cancer in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Non-small cell lung cancer with stage IA-IIIA (8th edition TNM classification) planning to undergo curative surgery or to undergo neoadjuvant therapy
- • Solid nodules \>1 cm or ground-glass nodules \>1.5 cm on imaging
- • No history of malignancies other than non-small cell lung cancer in the past 5 years
- • Specimens are well preserved and imaging documents are accessible.
- Exclusion Criteria:
- • Age\<18 years old
- • Non-small cell lung cancer with pathologic stage IIIB-IV (8th edition TNM classification)
- • Pathology results confirmed not to be non-small cell lung cancer
- • History of malignancies other than non-small cell lung cancer in the past 5 years
About Peking University People's Hospital
Peking University People's Hospital is a leading clinical research institution in China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. Affiliated with Peking University, the hospital integrates cutting-edge research, comprehensive healthcare services, and a multidisciplinary team of experts to facilitate the development of new therapies and medical interventions. With a strong focus on patient safety and ethical standards, Peking University People's Hospital is dedicated to conducting rigorous clinical trials that contribute to the global medical community and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
Kezhong Chen, MD
Study Chair
Peking University People's Hospital
Guangxi Wang, PhD
Study Director
Peking University
Jiatao Zhang, MD
Study Director
Guangdong Provincial People's Hospital
Rong Yin, MD
Study Director
Jiangsu Cancer Institute & Hospital
Ziming Li, MD
Study Director
Shanghai Chest Hospital
Yintao Li, MD
Principal Investigator
Shandong Cancer Hospital and Institute
Zizi Zhou, MD
Principal Investigator
Shenzhen Third People's Hospital
Fang Wu, MD
Principal Investigator
Second Xiangya Hospital of Central South University
Jun Yin, MD
Principal Investigator
Shanghai Zhongshan Hospital
Yuan Cheng, MD
Principal Investigator
Peking University First Hospital
Quanfu Huang, MD
Principal Investigator
Wuhan Union Hospital, China
Xiaojun Zhu, PhD
Principal Investigator
China National Institute for Occupational Safety and Health (NIOSH/CDC)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported